{"id":"2ef3c0352625","type":"article","url":"https://hartvaat.nl/2025/12/22/therapeutische-herprogrammering-van-myeloide-cellen-via-sirp-vesikels-bij-acuut-/","title":"Therapeutische herprogrammering van myeloïde cellen via SIRPα-vesikels bij acuut nierletsel","title_en":"Therapeutic reprogramming of circulating myeloid cells via signal regulatory protein α extracellular vesicles in acute kidney injury","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01022-1/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01022-1/fulltext","authors":["Dong-U Shin","Min Kyoung Jo","Minjeong Kwon","Yewon Jeong","Bogyeong Cho","Seong A Kim","Ga-Eun Choi","Seohyun Kim","Seok Ho Song","Hyemin Joo","Hyun Jung Kim","Jung Pyo Lee","Jeonghwan Lee","In-San Kim","Gi-Hoon Nam"],"significance":5,"published":"2025-12-22","source_date":"2025-12-22","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This research describes therapeutic reprogramming of circulating myeloid cells using SIRPa extracellular vesicles as a novel treatment strategy for acute kidney injury. The approach targets the CD47 immune checkpoint to modulate inflammatory cell infiltration.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"AKI kent hoge mortaliteit en progressierisico naar CKD. Dit onderzoek beschrijft therapeutische herprogrammering van circulerende myeloïde cellen via signal regulatory protein α extracellulaire vesikels als nieuwe behandelstrategie.","abstract_original":"Acute kidney injury (AKI) presents significant clinical challenges, with high mortality and progression risk to chronic kidney disease. Mechanisms remain incompletely understood and disease-specific therapies are lacking. Recent evidence highlights the pivotal role of infiltrating myeloid cells in perpetuating kidney inflammation. CD47, a key cell surface immune checkpoint protein, is upregulated in inflammation and regulates myeloid cell infiltration, making it an attractive therapeutic target."}